Search

Displaying results 5921 - 5930 of 9709 in total
  1. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

  2. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown. … Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women.[L9635] Bremelanotide does not interact with alcohol.

  3. Drug

    Eptacog alfa pegol (activated)

    go.drugbank.com/drugs/DB11661
    Investigational

    A With Inhibitors. … Eptacog alfa pegol (activated) has been used in trials studying the prevention and treatment of Haemophilia A, Haemophilia B, Congenital Bleeding Disorder, Haemophilia B With Inhibitors, and Haemophilia

  4. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.

    Synonyms: L-threitol-1,4-dimethanesulfonate
  5. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. … As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces erythropoiesis.

  6. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. … [A20298,A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage

  7. Drug

    Dutogliptin

    go.drugbank.com/drugs/DB11723
    Investigational

    Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.

  8. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Tetrahydrocannabivarin

    go.drugbank.com/drugs/DB11755
    Investigational

    Further evidence has also shown that THCV acts as an agonist of GPR55 and l-α-lysophosphatidylinositol (LPI) [A32974]. … Compared to THC which demonstrates its effects through weak partial agonist activity of both endocannabinoid receptors Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R), THCV acts as a CB1 antagonist and a

  10. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades … [A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.